FENC · Insider Trading
Fennec Pharmaceuticals Inc. Common Stock
Every open-market purchase and sale reported by FENC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-13 | Pierre Sargis Sayad | Chief Medical Officer | A | +3,846 | +$21.27K |
| 2026-10-13 | Jeffrey S. Hackman | Chief Executive Officer | A | +2,224 | +$12.30K |
| 2026-10-13 | Terry L Evans | Chief Commercial Officer | A | +2,326 | +$12.86K |
| 2026-10-13 | Christiana Marie Cioffi | Chief Strategy Officer | A | +3,946 | +$21.82K |
| 2026-10-13 | Robert Andrade | CHIEF FINANCIAL OFFICER | A | +3,846 | +$21.27K |
| 2026-10-01 | Christiana Marie Cioffi | Chief Strategy Officer | A | +156 | — |
| 2026-10-01 | Pierre Sargis Sayad | Chief Medical Officer | A | +168 | — |
| 2026-10-01 | Robert Andrade | CHIEF FINANCIAL OFFICER | A | +1,703 | — |
| 2026-10-01 | Terry L Evans | Chief Commercial Officer | A | +168 | — |
| 2026-10-01 | Jeffrey S. Hackman | Chief Executive Officer | A | +1,159 | — |
| 2026-09-16 | Marco Maria Brughera | Director | MIXED | — | −$127.16K |
| 2026-09-01 | Rosty Raykov | — | MIXED | −7,222 | −$121.10K |
| 2026-08-31 | Robert Andrade | CHIEF FINANCIAL OFFICER | A | +1,703 | — |
| 2026-08-31 | Pierre Sargis Sayad | Chief Medical Officer | MIXED | −11,832 | −$146.16K |
| 2026-08-31 | Christiana Marie Cioffi | Chief Strategy Officer | A | +156 | — |
| 2026-08-31 | Terry L Evans | Chief Commercial Officer | A | +168 | — |
| 2026-08-31 | Jeffrey S. Hackman | Chief Executive Officer | A | +1,159 | — |
| 2026-08-28 | Robert Andrade | CHIEF FINANCIAL OFFICER | MIXED | −53,072 | −$771.67K |
| 2026-08-04 | Rosty Raykov | — | Sell | −10,000 | −$95.80K |
| 2026-08-03 | Rosty Raykov | — | A | +2,778 | — |
| 2026-08-03 | Christiana Marie Cioffi | Chief Strategy Officer | A | +156 | — |
| 2026-08-03 | Terry L Evans | Chief Commercial Officer | A | +168 | — |
| 2026-08-03 | Robert Andrade | CHIEF FINANCIAL OFFICER | A | +1,703 | — |
| 2026-08-03 | Jeffrey S. Hackman | Chief Executive Officer | A | +1,159 | — |
| 2026-08-03 | Pierre Sargis Sayad | Chief Medical Officer | A | +168 | — |
| 2026-07-02 | Rosty Raykov | — | MIXED | +8,776 | −$61.71K |
| 2026-07-01 | Terry L Evans | Chief Commercial Officer | A | +168 | — |
| 2026-07-01 | Jeffrey S. Hackman | Chief Executive Officer | A | +1,159 | — |
| 2026-07-01 | Robert Andrade | CHIEF FINANCIAL OFFICER | A | +1,703 | — |
| 2026-07-01 | Christiana Marie Cioffi | Chief Strategy Officer | A | +156 | — |
| 2026-07-01 | Pierre Sargis Sayad | Chief Medical Officer | A | +168 | — |
| 2026-06-10 | Khalid Islam | Director | A | +25,000 deriv. | — |
| 2026-06-10 | Jodi A Cook | Director | A | +20,000 deriv. | — |
| 2026-06-10 | Chris A Rallis | Director | A | +20,000 deriv. | — |
| 2026-06-10 | Marco Maria Brughera | Director | A | +20,000 deriv. | — |
| 2026-06-02 | Rosty Raykov | Director | MIXED | +8,628 | −$55.55K |
| 2026-06-01 | Terry L Evans | Chief Commercial Officer | A | +168 | — |
| 2026-06-01 | Robert Andrade | CHIEF FINANCIAL OFFICER | A | +1,703 | — |
| 2026-06-01 | Pierre Sargis Sayad | Chief Medical Officer | A | +168 | — |
| 2026-06-01 | Christiana Marie Cioffi | Chief Strategy Officer | A | +156 | — |
| 2026-06-01 | Jeffrey S. Hackman | Chief Executive Officer | A | +1,159 | — |
| 2026-05-12 | Chris A Rallis | Director | MIXED | +5,998 | −$23.76K |
| 2026-05-01 | Terry L Evans | Chief Commercial Officer | M | +168 | — |
| 2026-05-01 | Robert Andrade | CHIEF FINANCIAL OFFICER | M | +1,703 | — |
| 2026-05-01 | Christiana Marie Cioffi | Chief Strategy Officer | M | +155 | — |
| 2026-05-01 | Pierre Sargis Sayad | Chief Medical Officer | M | +168 | — |
| 2026-05-01 | Jeffrey S. Hackman | Chief Executive Officer | M | +1,159 | — |
| 2026-05-01 | Rosty Raykov | Director | MIXED | +7,595 | −$31.54K |
| 2026-04-02 | Terry L Evans | Chief Commercial Officer | M | +20,679 | — |
| 2026-04-02 | Pierre Sargis Sayad | Chief Medical Officer | M | +20,679 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Southpoint GP, LP | 10%+ Owner | 3,744,741 | $38.01M |
| Southpoint GP, LLC | 10%+ Owner | 2,744,741 | $27.86M |
| Robert Andrade | CHIEF FINANCIAL OFFICER | 246,855 | $2.51M |
| Khalid Islam | Director | 143,333 | $1.45M |
| Rosty Raykov | Director | 124,411 | $1.26M |
| Jeffrey S. Hackman | Chief Executive Officer | 69,685 | $707.30K |
| Chris A Rallis | Director | 63,077 | $640.23K |
| Christiana Marie Cioffi | Chief Strategy Officer | 28,746 | $291.77K |
| Terry L Evans | Chief Commercial Officer | 24,013 | $243.73K |
| Marco Maria Brughera | Director | 15,545 | $157.78K |
| Pierre Sargis Sayad | Chief Medical Officer | 13,533 | $137.36K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the FENC quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.